Pazopanib and pancreatic toxicity: a case report

Marco Russano1, Bruno Vincenzi2, Olga Venditti3

  • 1Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy. m.russano@unicampus.it.

BMC Research Notes
|May 14, 2015
PubMed
Summary

Pazopanib, a tyrosine-kinase inhibitor for advanced renal cell carcinoma, can cause asymptomatic increases in pancreatic enzymes. Careful monitoring is recommended during treatment, as toxicity may not be dose-dependent.